sintilimab + albumin-bound paclitaxel + oxaliplatin + capecitabine

This refers to a specific multi-drug combination chemo-immunotherapy regimen being investigated at Ruijin Hospital in Shanghai, China, for the treatment of advanced gastric cancer, particularly cases with retroperitoneal (para-aortic) lymph node metastasis. The regimen, evaluated in the DRAGON-06 trial, combines the PD-1 immune checkpoint inhibitor sintilimab with a cytotoxic chemotherapy backbone consisting of nanoparticle albumin-bound paclitaxel (nab-paclitaxel), oxaliplatin, and capecitabine (or S-1). This protocol is typically employed as a conversion therapy intended to shrink tumors and metastases to allow for subsequent D2 surgical resection and radiotherapy. Sintilimab enhances anti-tumor immune responses by blocking the PD-1 receptor, while the chemotherapy components provide cytotoxic effects through microtubule stabilization (paclitaxel), DNA cross-linking (oxaliplatin), and inhibition of thymidylate synthase (capecitabine).

Other names

sintilimab + nab-paclitaxel + oxaliplatin + capecitabinesintilimab + nab-paclitaxel + SOXsintilimab + nab-paclitaxel + CAPOXalbumin + paclitaxel-Ruijin Hospital-gastric cancer